Dr. Luke M. Webb, MD
Internal Medicine (Internal Medicine Physician)
2709 N Tejon St
Colorado Springs, CO 80907
Who else practices at this address →
El Paso County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Tennessee, Hsc, College of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 213
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Tennessee, Hsc, College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
TN license MD0000039136 -
Allergy & Immunology Physician
TN license 39136
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uch-Memorial Health System Colorado Springs, CO
- Centura Health-Penrose St Francis Health Services Colorado Springs, CO
Medical groups
- Asthma and Allergy Associates, PC (13 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 213
- Services billed
- 11,204
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 3,770 | 57 |
| Professional service for preparation and provision of 1 or more antigens | 1,348 | 61 |
| Professional service for multiple injections of allergen | 938 | 48 |
| Professional service for single injection of allergen | 571 | 26 |
| Test for allergy using allergenic extract injected into skin | 314 | 18 |
| Established patient office or other outpatient visit, 30-39 minutes | 162 | 112 |
| Test to measure rate of airflow | 80 | 63 |
| New patient office or other outpatient visit, 30-44 minutes | 36 | 36 |
| New patient office or other outpatient visit, 45-59 minutes | 28 | 28 |
| Established patient office or other outpatient visit, 20-29 minutes | 18 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Colorado Springs, CO | 152 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Colorado Springs, CO | 54 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Colorado Springs, CO | 45 |
| Dupixent Pen (dupilumab) Other prescribers in Colorado Springs, CO | 41 |
| Ipratropium Bromide Other prescribers in Colorado Springs, CO | 39 |
| Azelastine Hcl Other prescribers in Colorado Springs, CO | 36 |
| Tezspire (tezepelumab-ekko) | 34 |
| Fluticasone Propionate Other prescribers in Colorado Springs, CO | 34 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Colorado Springs, CO | 26 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Colorado Springs, CO | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 96 payments worth $18,673 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $17,533 |
|---|---|
| Genzyme Corporation | $176 |
| Novartis Pharmaceuticals Corporation | $131 |
| Genentech USA, Inc. | $100 |
| Regeneron Healthcare Solutions, Inc. | $97.23 |
| Pfizer Inc. | $87.52 |
| Takeda Pharmaceuticals U.S.A., Inc. | $70.92 |
| Pharming Healthcare, Inc. | $66.87 |
| Compensation for services other than consulting (speaking, faculty) | $16,650 |
|---|---|
| Food and Beverage | $1,994 |
| Consulting Fee | $28.57 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $2,800 |
| AstraZeneca Pharmaceuticals LP Oct 9, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $2,350 |
| AstraZeneca Pharmaceuticals LP Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $1,850 |
| AstraZeneca Pharmaceuticals LP May 19, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $1,850 |
| AstraZeneca Pharmaceuticals LP Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $1,850 |
| AstraZeneca Pharmaceuticals LP Sep 22, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $1,400 |
| AstraZeneca Pharmaceuticals LP Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $1,400 |
| AstraZeneca Pharmaceuticals LP Sep 22, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $925 |
| AstraZeneca Pharmaceuticals LP Feb 18, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $450 |
| AstraZeneca Pharmaceuticals LP Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $450 |
All 17 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Adma Biomanufacturing LLC Dec 5, 2025 | Consulting Fee | $28.57 |
| AstraZeneca Pharmaceuticals LP Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $450 |
| AstraZeneca Pharmaceuticals LP Oct 9, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $2,350 |
| AstraZeneca Pharmaceuticals LP Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $1,400 |
| AstraZeneca Pharmaceuticals LP Sep 22, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $1,400 |
| AstraZeneca Pharmaceuticals LP Sep 22, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $925 |
| AstraZeneca Pharmaceuticals LP Aug 5, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $250 |
| AstraZeneca Pharmaceuticals LP Jul 17, 2025 | Compensation for services other than consulting (speaking, faculty) FASENRA · Respiratory Company’s descriptionSpeaker Fee | $150 |
| AstraZeneca Pharmaceuticals LP Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $2,800 |
| AstraZeneca Pharmaceuticals LP Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $1,850 |
| AstraZeneca Pharmaceuticals LP May 21, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $450 |
| AstraZeneca Pharmaceuticals LP May 19, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $1,850 |
| AstraZeneca Pharmaceuticals LP Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) FASENRA · Respiratory Company’s descriptionSpeaker Fee | $125 |
| AstraZeneca Pharmaceuticals LP Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) FASENRA · Respiratory Company’s descriptionSpeaker Fee | $100 |
| AstraZeneca Pharmaceuticals LP Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) FASENRA · Respiratory Company’s descriptionSpeaker Fee | $250 |
| AstraZeneca Pharmaceuticals LP Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $1,850 |
| AstraZeneca Pharmaceuticals LP Feb 18, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $450 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $494,431 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in…
Teva Pharmaceuticals USA, Inc. - A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
Eli Lilly and Company · Active, not recruiting · NCT06339008 - A 52-week, randomised, double-blind, double-dummy, parallel group, mul
GlaxoSmithKline, LLC. - A phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.